SCI时时刷

search
Chapter One - mRNA-based therapies: Preclinical and clinical applications
At the fundamental level, messenger RNA (mRNA)-based therapeutics involves the delivery of in vitro-transcribed (IVT) mRNA...
Chapter Two - Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases
Volume 372, 2022, Pages 55-96AbstractInborn errors of metabolism (IEM) encompass a group of monogenic diseases affecting b...
Chapter Three - Applications of self-replicating RNA
Volume 372, 2022, Pages 97-157AbstractSelf-replicating RNA viral vectors have been engineered for both prophylactic and th...
Chapter Four - Present and future of lipid nanoparticle-mRNA technology in phenylketonuria disease treatment
Volume 372, 2022, Pages 159-174AbstractPhenylketonuria (PKU) is a metabolic rare disease characterized by a failure of the...
Chapter Five - RNA gene editing in the eye and beyond: The neglected tool of the gene editing armatorium?
Volume 372, 2022, Pages 175-205AbstractRNA editing allows correction of pathological point mutations without permanently a...
Chapter Six - mRNA delivery technologies: Toward clinical translation
Volume 372, 2022, Pages 207-293AbstractMessenger RNA (mRNA)-therapies have recently taken a huge step toward clinic thanks...
Chapter Seven - Advances in mRNA vaccines
Volume 372, 2022, Pages 295-316AbstractmRNA vaccines have been increasingly recognized as a powerful vaccine platform sinc...
Targeting amino acid metabolism in cancer
Available online 15 September 2022AbstractMetabolic rewiring is a characteristic hallmark of cancer cells. This phenomenon...
Fasting and cancer responses to therapy
Available online 15 September 2022AbstractThe therapeutic outcome of multiple anticancer regimens relies upon a fine balan...
Applications of self-replicating RNA
Available online 17 August 2022AbstractSelf-replicating RNA viral vectors have been engineered for both prophylactic and t...
RNA gene editing in the eye and beyond: The neglected tool of the gene editing armatorium?
Available online 17 August 2022AbstractRNA editing allows correction of pathological point mutations without permanently a...
Chapter One - The role of dendritic cells in the immune niche of the peritoneum
Volume 371, 2022, Pages 1-14AbstractDendritic cells (DCs) are professional antigen presenting cells that play an important...
Chapter Two - T cells in the peritoneum
Volume 371, 2022, Pages 15-41AbstractThe peritoneal cavity is a fluid-packed area that houses most of the abdominal organs...
Chapter Three - Innate immune response to peritoneal bacterial infection
Volume 371, 2022, Pages 43-61AbstractSpontaneous and secondary peritoneal infections, mostly of bacterial origin, easily s...
Chapter Four - The tumor immune microenvironment in peritoneal carcinomatosis
Volume 371, 2022, Pages 63-95AbstractOne in four patients with colorectal cancer, 40% of gastric cancer patients, and 60% ...
Chapter Five - Immune response and locoregional treatments for peritoneal carcinomatosis
Volume 371, 2022, Pages 97-116AbstractPeritoneal Carcinomatosis (PC) is considered as a terminal disease with short surviv...
Chapter Six - Omentum: Friend or foe in ovarian cancer immunotherapy?
Volume 371, 2022, Pages 117-131AbstractOvarian cancer often spreads out of the ovary before a patient is diagnosed and is ...
Innate immune response to peritoneal bacterial infection
Available online 12 July 2022AbstractSpontaneous and secondary peritoneal infections, mostly of bacterial origin, easily s...
mRNA delivery technologies: Toward clinical translation
Messenger RNA (mRNA)-therapies have recently taken a huge step toward clinic thanks to the first mRNA-based medicinal prod...
Immune response and locoregional treatments for peritoneal carcinomatosis
Available online 8 July 2022AbstractPeritoneal Carcinomatosis (PC) is considered as a terminal disease with short survival...
Chapter One - Impact of tumor microenvironment on adoptive T cell transfer activity
Volume 370, 2022, Pages 1-31AbstractRecent advances in immunotherapy have revolutionized the treatment of cancer. The use ...
Chapter Two - Dendritic cell transfer for cancer immunotherapy
Volume 370, 2022, Pages 33-64AbstractDendritic cells (DCs) play a major role in cancer immunosurveillance as they bridge i...
Chapter Four - Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment
Volume 370, 2022, Pages 123-147AbstractAdoptive T cell therapies based on chimeric antigen receptors (CAR-T) are emerging ...
Chapter Five - What will (and should) be improved in CAR immunotherapy?
Volume 370, 2022, Pages 149-161AbstractChimeric antigen receptor (CAR) is probably one of the most successful proposals fo...
Chapter Six - Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy
Volume 370, 2022, Pages 163-192AbstractCancer is a leading cause of death worldwide and, despite new targeted therapies an...
Dendritic cell transfer for cancer immunotherapy
Available online 29 June 2022AbstractDendritic cells (DCs) play a major role in cancer immunosurveillance as they bridge i...
Chapter Three - Applications of trimerbodies in cancer immunotherapy
Volume 369, 2022, Pages 71-87AbstractTrimerbodies, with their unique structural and functional properties, are the basis o...
Chapter Four - Anticalin®-based therapeutics: Expanding new frontiers in drug development
Volume 369, 2022, Pages 89-106AbstractAnticalin proteins are a novel class of clinical-stage biopharmaceuticals with high ...
Chapter Five - Overcoming the limitations of cytokines to improve cancer therapy
Volume 369, 2022, Pages 107-141AbstractCytokines are pleiotropic soluble proteins used by immune cells to orchestrate a co...